3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
85
Breast Neoplasms
37
Lung Neoplasms
27
Triple Negative Breast Neoplasms
25
Ovarian Neoplasms
21
Squamous Cell Carcinoma of Head and Neck
20
Fallopian Tube Neoplasms
16
Small Cell Lung Carcinoma
15
Neoplasm Metastasis
14
Endometrial Neoplasms
13
Esophageal Neoplasms
11
Neoplasms
10
Prostatic Neoplasms
9
Colorectal Neoplasms
9
Head and Neck Neoplasms
8
Carcinoma
8
Urinary Bladder Neoplasms
7
Uterine Cervical Neoplasms
6
Pancreatic Neoplasms
6
Oropharyngeal Neoplasms
6
Lymphoma, Large B-Cell, Diffuse
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Laryngeal Neoplasms
5
Carcinoma, Transitional Cell
5
Carcinoma, Squamous Cell
5
Stomach Neoplasms
4
Mouth Neoplasms
4
Melanoma
4
Carcinoma, Ovarian Epithelial
4
Urothelial Cancer
3
Interventions
tremelimumab
1
durvalumab
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Non Small Cell Lung Cancer NSCLC
×
Carboplatin
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA